Switch to everolimus for sirolimus-induced pneumonitis in a liver transplant recipient--not all proliferation signal inhibitors are the same: a case report

P De Simone; S Petruccelli; A Precisi; P Carrai; R Doria; F Menichetti; F Filipponi

doi:10.1016/j.transproceed.2007.09.040

Switch to everolimus for sirolimus-induced pneumonitis in a liver transplant recipient--not all proliferation signal inhibitors are the same: a case report

Transplant Proc. 2007 Dec;39(10):3500-1. doi: 10.1016/j.transproceed.2007.09.040.

Authors

P De Simone¹, S Petruccelli, A Precisi, P Carrai, R Doria, F Menichetti, F Filipponi

Affiliation

¹ Liver Transplant Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.

PMID: 18089420
DOI: 10.1016/j.transproceed.2007.09.040

Abstract

We report a 62-year-old female liver transplant patient who presented with sirolimus (SIR)-related pneumonitis (SIP) treated with a switch to everolimus (EVER). At 13-month follow-up, the patient is on EVER monotherapy with no recurrence of SIP. Despite common mechanisms of action, the safety profile of EVER is different from SIR, and a switch from SIR to EVER should be contemplated in cases of SIP to allow patients to benefit from the antifibrotic properties of antiproliferative immunosuppressants.

Publication types

Case Reports

MeSH terms

Everolimus
Female
Humans
Immunosuppressive Agents / adverse effects
Immunosuppressive Agents / therapeutic use*
Liver Transplantation / immunology*
Middle Aged
Pneumonia / chemically induced*
Sirolimus / adverse effects*
Sirolimus / analogs & derivatives*
Sirolimus / therapeutic use
Treatment Outcome

Substances

Immunosuppressive Agents
Everolimus
Sirolimus